BamSEC and AlphaSense Join Forces
Learn More

Dova Pharmaceuticals Inc. – Material Contracts

Formerly NASDAQ: DOVA
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 7 pages First Amendment to Office Lease Agreement
12/34/56
EX-10.1
from 8-K 13 pages First Amendment to the Co-Promotion Agreement by and Between Dova Pharmaceuticals, Inc. and Bausch Health US, LLC July 1, 2019
12/34/56
EX-10.29
from 10-K 14 pages Employment Agreement
12/34/56
EX-10.28
from 10-K 19 pages Employment Agreement
12/34/56
EX-10.3
from 8-K 2 pages Dova Pharmaceuticals, Inc. Second Amended and Restated Non-Employee Director Compensation Policy Effective December 19, 2019
12/34/56
EX-10.2
from 8-K 11 pages Dova Pharmaceuticals Restricted Stock Unit Grant Notice
12/34/56
EX-10.1
from 8-K 30 pages Dova Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan Adopted by the Board of Directors: June 14, 2017 Approved by the Stockholders: June 15, 2017 Amended by the Compensation Committee: December 19, 2018 Ipo Date: June 28, 2017
12/34/56
EX-10.3
from 10-Q 5 pages Amended and Restated Transition Services Agreement by and Between Eisai Inc. and Akarx, Inc. Dated as of April 1, 2018 Confidential Treatment Has Been Requested for Portions of This Exhibit. the Copy Filed Herewith Omits the Information Subject to a Confidentiality Request. Omissions Are Designated [***]. a Complete Version of This Exhibit Has Been Filed Separately With the Securities and Exchange Commission
12/34/56
EX-10.2
from 10-Q 20 pages Co-Promotion Agreement by and Between Dova Pharmaceuticals, Inc. and Valeant Pharmaceuticals North America LLC September 26, 2018 Confidential Treatment Has Been Requested for Portions of This Exhibit. the Copy Filed Herewith Omits the Information Subject to a Confidentiality Request. Omissions Are Designated [***]. a Complete Version of This Exhibit Has Been Filed Separately With the Securities and Exchange Commission
12/34/56
EX-10.3
from 10-Q 42 pages First Amendment to Commercial Outsourcing Master Services Agreement Interim Direct Model
12/34/56
EX-10.1
from 8-K 25 pages Dova Pharmaceuticals, Inc. Common Stock ($0.001 Par Value Per Share) At-The-Market Equity Offering Sales Agreement
12/34/56
EX-10.1
from 8-K 55 pages Lease Agreement
12/34/56
EX-10.3
from 10-Q 2 pages Dova Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy Effective January 1, 2018
12/34/56
EX-10.2
from 10-Q 3 pages Amendment to Services Agreement
12/34/56
EX-10.1
from 8-K 12 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 5 pages First Amendment to Sublease Agreement
12/34/56
EX-10.18
from S-1/A 49 pages Sublease Agreement
12/34/56
EX-10.12
from S-1/A 14 pages Indemnification Agreement
12/34/56
EX-10.11
from S-1/A 27 pages Dova Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan Adopted by the Board of Directors: June 14, 2017 Approved by the Stockholders: June 15, 2017 Ipo Date: , 2017
12/34/56
EX-10.17
from S-1/A 42 pages Supply Agreement Between Eisai Inc. and Akarx, Inc. Dated as of June 9, 2017
12/34/56